Loading organizations...
InnoVen Capital is Asia's leading venture debt firm, providing debt-based financing to technology startups across growth stages, headquartered in Mumbai, India, with regional offices in Singapore and Beijing. The firm had secured $282.0 million in total funding as of April 2022, having deployed over $500 million to more than 200 companies by 2019. In 2019, InnoVen raised $200 million in new capital, with major shareholders Temasek and United Overseas Bank (UOB) each contributing $100 million. Its portfolio includes notable technology startups such as Byju's, Cure.fit, PharmEasy, OfBusiness, and Infra.market. Led by Managing Partner & CEO Ashish Sharma, InnoVen Capital was established in 2015 following Temasek's acquisition of Silicon Valley Bank's Indian branch. Its business model centers on innoVen operates as a non-banking finance company in India and manages venture debt funds, generating returns through debt financing to startups.
Innoven Partners has 1 tracked investment across 1 company. The latest tracked deal is $22.6M Series D in Kiora Pharmaceuticals in January 2010.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 8, 2010 | Kiora Pharmaceuticals | $22.6M Series D | — | Emerging Capital Partners, Medicis Capital, Natixis, Ventech |
